Findings from a new analysis show that there is a lower risk of nocturnal hypoglycaemia with Lanctus in comparison to NPH insulin.
Sanofi-aventis have announced results of a new analysis that found a significantly lower risk of nocturnal hypoglycaemia with Lantus (insulin glargine [rDNA] injection) as compared to NPH insulin.
A separate post-hoc sub-analysis found a greater HbA1c and FBG reduction for elderly patients over 65 years of age taking Lantus as compared to NPH insulin. Both analyses were presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
The first analysis demonstrated that patients treated with Lantus, in around 6 months, 1 in 8 patients using Lantus would avoid a confirmed hypoglycaemic event compared to patients using NPH. The analysis also found that there was a significantly lower risk of nocturnal hypoglycaemia with Lantus treatment and that daytime symptomatic hypoglycaemia tended to be lower with Lantus vs NPH, but the differences were not statistically significant.
“The avoidance of confirmed symptomatic hypoglycemic events with Lantus is highly meaningful for patients,” said Professor Philip Home, Newcastle University, UK, author of the study.
The studies also found that there was a significantly lower risk of nocturnal severe hypoglycaemia, which may help patients better adhere to their insulin therapy.
To find out more, please click on the link below: